Evaluation of the relationship between prestin serum biomarker and sensorineural hearing loss: a case–control study

Asli, Rastin Hosseinzadeh; Akbarpour, Maliheh; Lahiji, Mahtab Raji; Leyli, Ehsan Kazemnezhad; Pastadast, Masoume; Ramezani, Hedieh; Nemati, Shadman

doi:10.1007/s00405-022-07586-2

Cited by 6 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is similar in design to that of Asli et al [12]. Our findings diverge in that Asli et al concluded that the prestin level was significantly associated with the severity of hearing loss, whereas we found that prestin levels were not significantly associated with the severity of hearing loss beyond the moderate SNHL range.…”

Section: Discussionsupporting

confidence: 62%

“…There have been promising experimental results in noiseand ototoxin-induced models [2][3][4][5][6][7] that have supported a promising role for prestin as a biomarker. While human studies have also yielded support for the concept [8][9][10][11][12][13][14], additional results are needed to help translate prestin as a biomarker from the research setting to the clinical setting. This is particularly important since prestin is also expressed by cardiac muscles, where it serves to amplify cardiac function [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of Serum Prestin Levels to the Severity of Sensorineural Hearing Loss

Al Samarrai,

Mahdi,

Parham

2024

Cureus

View full text Add to dashboard Cite

Objective: Prestin is an outer hair cell (OHC) protein responsible for increasing cochlear sensitivity and has been proposed as a biomarker. We aimed to evaluate whether the serum prestin level is related to the severity of chronic sensorineural hearing loss (SNHL).Methods: Ninety subjects were recruited from the patient base at Samarra public hospitals and clinics in Iraq from January to October of 2022. They were divided into three groups equally: a group of healthy people without hearing loss (G0), a group with moderate SNHL (G1), and a group with severe SNHL (G2). The subjects ranged from 20 to 80 years of age and included 51 males and 39 females. Blood samples were collected, then serum was separated, and enzyme-linked immunosorbent assays were performed to quantify the levels of prestin.Results: Hearing thresholds were sequentially statistically higher across the three groups. While prestin levels were significantly higher in G1 and G2 than that in G0, there were no differences between the G1 and G2 levels. Serum prestin levels were positively correlated with hearing thresholds in G1, but not G2. Conclusion:Our results suggest that in the clinical setting, prestin is sensitive to chronic mild to moderate SNHL (i.e., up to 40-60 dB), not more severe loss. This range is consistent with the added sensitivity provided by OHCs in the cochlea and provides support for prestin as a biomarker of OHC-mediated SNHL.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Relationship of Serum Prestin Levels to the Severity of Sensorineural Hearing Loss

Al Samarrai,

Mahdi,

Parham

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Several other groups have since reported increased prestin levels in experimental models of ototoxicity using cisplatin [8,9] and amikacin [8] and in patients undergoing treatment with cisplatin [9,10]. Many have explored and reported promising results on the value of prestin as a biomarker in human SNHL [11][12][13], including noise-induced [14], lead toxicity [15], presbycusis [16], sudden SNHL [17] and Meniere's disease [18].…”

Section: Introductionmentioning

confidence: 99%

Automated western blot analysis of ototoxin-induced prestin burst in the blood after cyclodextrin exposure

Harrison

Driscoll

Farnsworth

et al. 2023

Preprint

View full text Add to dashboard Cite

In the clinical realm, we primarily rely on audiological measures for diagnosis and surveillance of sensorineural hearing loss (SNHL) and have limited therapeutic options. We have proposed a blood-based biomarker approach to overcome this challenge by measuring the outer hair cell’s (OHC) electromotile protein, prestin, in the blood. In a guinea pig model of cyclodextrin (CDX) ototoxicity, using western blots, we show that prestin in the blood may have several different forms and specifically the ~ 134 kDa form spikes after ototoxin ablation of OHCs. This form appears to be a glycosylated dimer likely secreted by the inner ear as exosomes reflecting increased expression after ototoxin exposure. These results suggest that the ~ 134 kDa dimer may serve as a biomarker for early detection of ototoxicity in the clinical setting. However, because prestin can still be measured in the blood after total ablation of OHCs, its ability to inform on OHC health is restricted to a narrow window after ototoxin-induced injury. Monitoring prestin, when using therapeutics with ototoxic properties, could guide dosage and administration schedule to minimize damage.

show abstract

“…By using a sandwich enzyme-linked immunosorbent assay (ELISA), Prestin was detected in the bloodstream of humans [13][14][15], rats [16,17], guinea pigs [18,19], and mice [20]. Several reports suggested that Prestin in the bloodstream could be used as a biomarker for hearing loss such as idiopathic sudden sensorineural hearing loss [13-15, 21, 22], noise-induced hearing loss [16,17,[23][24][25], sensory hearing loss [26][27][28], age-related hearing loss [29], ototoxic regents induced hearing loss, such as HPβCD [30] and cisplatin [18][19][20]31], and also hearing loss observed in various diseases like Meniere's Disease and Vestibular Migraine [32], COVID-19 [33], lead poison [34], and even surgical related damage [21]. However, the data reported in several studies lack proper negative controls and show inconsistency [13,14].…”

Section: Introductionmentioning

confidence: 99%

Outer Hair Cell Motor Protein, Prestin, Is Not a Reliable Serological Biomarker for Mouse Cochlear Damage

Zheng,

Zhou,

Fuentes

et al. 2024

Preprint

View full text Add to dashboard Cite

The motor protein Prestin found in the outer hair cells (OHCs) of the inner ear is responsible for producing high sensitivity and sharp frequency selectivity for mammalian hearing. Some studies have suggested that Prestin could serve as a serological biomarker for cochlear damage since OHCs are highly vulnerable to damage from various sources of insults. However, the reported data are inconsistent and lack appropriate negative controls. To investigate this further, we measured Prestin quantities in the bloodstream using ELISA kits from different companies. Wildtype (WT) mice were exposed to different ototoxic treatments, including noise exposure and ototoxic reagents that kill OHCs rapidly. Prestin-knockout (KO) mice were used as a negative control. Our data show that some ELISA kits were not able to detect Prestin specifically. The ELISA kit that could detect Prestin protein from cochlear homogenates failed to detect Prestin in the bloodstream despite significant damage to OHCs in cochleae. Furthermore, the optical densities of samples, which correlate to Prestin quantities, were significantly influenced by hemolysis in the samples. In conclusion, Prestin from OHCs is not a sensitive and reliable serological biomarker for detecting cochlear damage in mice.

show abstract

Evaluation of the relationship between prestin serum biomarker and sensorineural hearing loss: a case–control study

Cited by 6 publications

References 20 publications

Relationship of Serum Prestin Levels to the Severity of Sensorineural Hearing Loss

Relationship of Serum Prestin Levels to the Severity of Sensorineural Hearing Loss

Automated western blot analysis of ototoxin-induced prestin burst in the blood after cyclodextrin exposure

Outer Hair Cell Motor Protein, Prestin, Is Not a Reliable Serological Biomarker for Mouse Cochlear Damage

Contact Info

Product

Resources

About